Polymorphous low-grade adenocarcinoma (PLGA) is the second most frequent type of malignant tumor of the minor salivary glands. We identified PRKD1 hotspot mutations encoding p.Glu710Asp in 72.9% of PLGAs but not in other salivary gland tumors. Functional studies demonstrated that this kinase-activating alteration likely constitutes a driver of PLGA.

] Department of Medical Biophysics University of Toronto Toronto Ontario Canada [2] Department of Pathology Virginia Mason Hospital and Seattle Medical Center Seattle Washington USA

] Department of Molecular Genetics Lerner Research Institute Cleveland Ohio USA [2] Robert J Tomsich Pathology and Laboratory Medicine Institute Taussig Cancer Center Cleveland Clinic Cleveland Ohio USA

] Department of Pathology Memorial Sloan Kettering Cancer Center New York New York USA [2]

] Department of Pathology Memorial Sloan Kettering Cancer Center New York New York USA [2] Instituto Português de Oncologia Oporto Portugal

] Department of Pathology Memorial Sloan Kettering Cancer Center New York New York USA [2] School of Pathology University of Milan Milan Italy

] Informatics and Bio Computing Program Ontario Institute for Cancer Research Toronto Ontario Canada [2] Department of Medical Biophysics University of Toronto Toronto Ontario Canada [3] Department of Pharmacology and Toxicology University of Toronto Toronto Ontario Canada

] Informatics and Bio Computing Program Ontario Institute for Cancer Research Toronto Ontario Canada [2] Ontario Cancer Institute Princess Margaret Cancer Centre University Health Network Toronto Onatrio Canada [3] Campbell Family Institute for Cancer Research Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada

] Informatics and Bio Computing Program Ontario Institute for Cancer Research Toronto Ontario Canada [2] Ontario Cancer Institute Princess Margaret Cancer Centre University Health Network Toronto Onatrio Canada [3] Campbell Family Institute for Cancer Research Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada [4] Department of Medical Biophysics University of Toronto Toronto Ontario Canada

] Instituto Português de Oncologia Francisco Gentil Lisbon Portugal [2] Faculdade de Medicina de Lisboa Lisbon Portugal

] Ontario Cancer Institute Princess Margaret Cancer Centre University Health Network Toronto Onatrio Canada [2] Campbell Family Institute for Cancer Research Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada

] Ontario Cancer Institute Princess Margaret Cancer Centre University Health Network Toronto Onatrio Canada [2] Campbell Family Institute for Cancer Research Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada [3] Department of Medical Biophysics University of Toronto Toronto Ontario Canada

] Ontario Cancer Institute Princess Margaret Cancer Centre University Health Network Toronto Onatrio Canada [2] Campbell Family Institute for Cancer Research Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada [3] Department of Medical Biophysics University of Toronto Toronto Ontario Canada [4] Department of Radiation Oncology Princess Margaret Hospital and University of Toronto Toronto Ontario Canada

Cancer Genomics Platform Ontario Institute for Cancer Research Toronto Ontario Canada

Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

Department of Pathology and Laboratory Medicine Charles University Prague Plzen Czech Republic

Department of Pathology Kaiser Permanente Woodland Hills Medical Center Woodland Hills California USA

Department of Pathology Memorial Sloan Kettering Cancer Center New York New York USA

Department of Pathology University Health Network Toronto Ontario Canada

Department of Pathology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA

Department of Pathology University of Virginia Medical Center Charlottesville Virginia USA

Department of Pathology Virginia Mason Hospital and Seattle Medical Center Seattle Washington USA

Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA

Informatics and Bio Computing Program Ontario Institute for Cancer Research Toronto Ontario Canada

Integrated Genomics Operation Center for Molecular Oncology Memorial Sloan Kettering Cancer Center New York New York USA

Western University London Ontario Canada

Comment In

Cancer Discov. 2014 Nov;4(11):1255. doi: 10.1158/2159-8290.CD-RW2014-208. PubMed

See more in PubMed

Barnes L, Eveson J, Reichart P & Sidransky D Pathology And Genetics of Head and Neck Tumours, (IARC Press, 2005).

Foschini MP & Eusebi V Pathology 41,48–56(2009). PubMed

Evans HL & Luna MA Am J Surg Pathol 24,1319–1328(2000). PubMed

Perez-Ordonez B, Linkov I & Huvos AG Histopathology 32,521–529(1998). PubMed

Weinreb I Adv Anat Pathol 20,367–377(2013). PubMed

Cappuzzo F et al. J Natl Cancer Inst 97,643–655(2005). PubMed

Rozengurt E Physiology (Bethesda) 26,23–33(2011). PubMed PMC

Gao J et al. Sci Signal 6,pl1(2013). PubMed PMC

Forbes SA et al. Nucleic Acids Res 39,D945–950(2011). PubMed PMC

Debnath J, Muthuswamy SK & Brugge JS Methods 30,256–268(2003). PubMed

Debnath J & Brugge JS Nat Rev Cancer 5,675–688(2005). PubMed

Weigelt B, Geyer FC & Reis-Filho JS Mol Oncol 4,192–208(2010). PubMed PMC

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands

SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets

Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG): An International Interobserver Study

Polymorphous adenocarcinoma of the salivary glands: reappraisal and update

Newly described salivary gland tumors

Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland

See more in PubMed

SRA
SRP045782, SRP045785